Skip to main content
Fig. 3 | Orphanet Journal of Rare Diseases

Fig. 3

From: Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)

Fig. 3

(a) Time to target wound closure and (b) proportion of patients with target wound closure by visita. ITT intent-to-treat. aITT population (N = 169). Patients were censored if they did not have a response within 3 months or withdrew early before the confirmation of their target wound closing. The Kaplan-Meier curves exceed the time limit of 3 months because the study duration for a fraction of patients was more than 3 months (nominal Month 3 visit could have occurred at Month 5)

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172